UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
03. April 2024 07:00 ET
|
Arch Biopartners
TORONTO, April 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that Anesthesia Clinical Trials Unit (ACTU), an...
Arch Biopartners Receives Permission From U.S. FDA to Proceed With Phase II Acute Kidney Injury Trial
27. Juni 2023 07:15 ET
|
Arch Biopartners
Approval from FDA to initiate Phase II trial with LSALT peptide to target cardiac surgery-associated acute kidney injury (CS-AKI)LSALT peptide targets dipeptidase-1 (DPEP-1), an enzyme known to...
Turkish Ministry of Health Approves Increase in Patient Recruitment into the Phase II Trial for LSALT Peptide
30. März 2021 07:57 ET
|
Arch Biopartners
TORONTO, March 30, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received approval from the Turkish Ministry...
First Patient Dosed in Phase II Trial to Treat Complications in COVID-19
16. Oktober 2020 07:00 ET
|
Arch Biopartners
TORONTO, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has dosed the first patient in the Phase II trial...
Broward Health Medical Center Becomes First Clinical Site in U.S. for Phase II Trial for LSALT Peptide
28. Juli 2020 08:13 ET
|
Arch Biopartners
TORONTO, July 28, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
ARCH BIOPARTNERS SAFELY COMPLETES EXPANDED DOSING OF METABLOK IN PHASE I HUMAN TRIAL AND BEGINS FOCUS ON PHASE II TRIAL
17. März 2020 11:21 ET
|
Arch Biopartners
TORONTO, March 17, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that it has safely completed dosing of the final...
Arch Biopartners Announces Metablok Achieves Primary Endpoints of Safety and Tolerability in Phase I Trial
18. Dezember 2019 09:27 ET
|
Arch Biopartners
TORONTO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Phase I human trial of Metablok (LSALT...
Arch Biopartners Announces Issuance of U.S. Patent for Dipeptidase-1 Inhibitor Drug for Use in Acute Kidney Injury
04. Dezember 2019 08:46 ET
|
Arch Biopartners
TORONTO, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
Arch Provides Interim Update on Phase I Trial for Metablok (LSALT Peptide)
07. November 2019 07:00 ET
|
Arch Biopartners
TORONTO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Phase I human trial of Metablok (LSALT...
Arch Scientists Publish Data on the Mechanism of Action and Efficacy of Lead Drug Candidate Metablok in the Prevention of Inflammation and Organ Damage
22. August 2019 12:24 ET
|
Arch Biopartners
TORONTO, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that a scientific team led by Dr. Donna Senger, Dr....